Session Chair Profile

Ph.D., Vice President, Cancer Immunology, Genentech

Biography
Ira Mellman came to Genentech in the Spring of 2007 as Vice President of Research Oncology, after more than 20 years as a faculty member at the Yale University School of Medicine, where he was chair of his department (Cell Biology), a member of the Ludwig Institute for Cancer Research, scientific director of the Yale Cancer Center, and Sterling Professor of Cell Biology and Immunobiology. Dr. Mellman has a BA from Oberlin College & Conservatory and a PhD in Genetics from Yale. He was a Postdoctoral Fellow at the Rockefeller University with Ralph Steinman, who received the Nobel Prize for the discovery of dendritic cells. His laboratory is known not only for advances in fundamental cell biology particularly in the area of membrane traffic (including the discovery of “endosomes”) but also for applying these insights to understanding the cellular basis of the immune response, especially dendritic cell function. He was also the founder of CGI Pharma, which was recently purchased by Gilead. Ira ran all of oncology research at Genentech until the end of 2013 when he decided to concentrate his efforts on the rapidly developing area of cancer immunotherapy and became Vice President of Cancer Immunology. Ira is a member of the National Academy of Sciences, American Academy of Arts & Sciences, the European Molecular Biology Organization, and the former Editor in Chief of the Journal of Cell Biology. He has also served on the editorial boards of Cell, the Journal of Experimental Medicine, EMBO Journal, among others. He also serves on the boards of the Society for the Immunotherapy of Cancer, the American Society for Cell Biology, and the Cancer Research Institute. He remains a frustrated composer and songwriter, and has recorded two CDs in the little-known genre of “bio-rock”.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Ira Mellman, Genentech

Human cells have been successfully used as treatment for blood cancers for decades but translating the promise to cell-based treatment for solid tumors has been slow. The advent of gene-editing techniques such as CRISPR, coupled with advances in our understanding of immunology and optimization of growing, manufacturing, transporting, storing, and handling specialized biological samples and materials is transforming the cell therapy field. We will hear in this session about some of the most promising work in the field, as well as the challenges in overcoming resistance

    Sessions:
  • Recent Advances in Cell-based Therapy (PANEL)
    Session Chair: Sascha Rutz, Genentech
    - Susie Jun, ArsenalBio
    - Elliot Norry, Adaptimmune
    - Tina Albertson, Lyell
    - Hy Levitsky, Century Therapeutics
  • Cell-based Therapy Challenges (PANEL)
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Arati Rao, PACT Pharma
    - Mark Kotter, bit.bio
    - Hy Levitsky, Century Therapeutics
  • Synergistic Drug Combinations Targeting Tumor and Microenvironment
  • Next-generation Supply Chain For Cell & Gene Therapies (PANEL)
    Session Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Ann Klein, Vineti
    - Tim Moore, Pact Pharma
    - Heidi Hunter, Cardinal Health
  • Biomarkers to Guide Immunotherapy
    Session Chair: Danny Wells, ImmunAI
    - Sanjeev Mariathasan, Genentech
    - Klaus Lindpaintner, InterVenn Bioscience
    - Lacey Padron, PICI
  • NaNots: A New Class of Immunotherapy
    - Lou Hawthorne, Nanotics
  • Advances in Multi-Omic Spatial Profiling
    Session Chair: Michael Rhodes, Nanostring
    - Chris Corless, OHSU
  • Engineered Therapeutics (PANEL)
    Session Chair: Paul Parren, Lava Therapeutics
    - Sonja Schrepfer, UCSF
    - Greg Lazar, Genentech